Xbrane Biopharma: Lucamzi approved by the FDA - Redeye
The FDA has approved Lucamzi, Xbrane’s Lucentis biosimilar, two days ahead of the 29 October BsUFA date. We give our initial comment and will return in more detail in connection with the Q3 report on Friday.
ANNONS
The FDA has approved Lucamzi, Xbrane’s Lucentis biosimilar, two days ahead of the 29 October BsUFA date. We give our initial comment and will return in more detail in connection with the Q3 report on Friday.
